In August 2016, The American Academy of Sleep Medicine (AASM) published a document entitled
Exploring The Economic Benefit of OSA Diagnosis and Treatment. In the publication (also published in thedocument
Hidden Health Crisis Costing America Billions), the 2015 cost for undiagnosed obstructive sleep apnea was $150 billion. Because the cost of treating OSA would be only one-third of the cost if left untreated, the cost-savings lost per year for leaving OSA untreated in the vast majority (80%) of candidates approaches (and certainly now exceeds) $100 billion per year in the United States.
In the
Testing link we emphasized that there are good clinical arguments for testing all patients with type 2 diabetes mellitus and drug-resistant hypertensives. Now we can appreciate the economic arguments that accrue to that vast untreated patient pool as well.
In particular, the Executive Summary of the AASM publication reports that "(d)irect economic costs can include comorbidities such as high blood pressure or diabetes, motor vehicle or workplace accidents, and compensating behaviors such as the substance abuse of pills, tobacco and alcohol. Indirect economic costs can include decreased productivity at work, reduced quality of life, and stress on interpersonal relationships."